Brokerages Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) PT at $47.62

BridgeBio Pharma, Inc. (NASDAQ:BBIOGet Free Report) has been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $47.62.

A number of brokerages recently issued reports on BBIO. HC Wainwright reiterated a “buy” rating and issued a $43.00 price target on shares of BridgeBio Pharma in a report on Thursday, June 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $70.00 price target on shares of BridgeBio Pharma in a report on Tuesday, May 28th. UBS Group lowered their price target on BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating for the company in a report on Tuesday, May 28th. JPMorgan Chase & Co. boosted their price target on BridgeBio Pharma from $35.00 to $45.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. Finally, Mizuho lowered their price target on BridgeBio Pharma from $60.00 to $53.00 and set a “buy” rating for the company in a report on Tuesday, March 5th.

View Our Latest Stock Report on BBIO

Insider Buying and Selling

In other BridgeBio Pharma news, Director Randal W. Scott sold 1,000 shares of BridgeBio Pharma stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $28.84, for a total transaction of $28,840.00. Following the completion of the sale, the director now directly owns 5,500 shares of the company’s stock, valued at approximately $158,620. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 24.66% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. YHB Investment Advisors Inc. acquired a new stake in BridgeBio Pharma during the 1st quarter valued at $34,000. Quarry LP purchased a new position in shares of BridgeBio Pharma during the 4th quarter worth $50,000. Assetmark Inc. raised its position in shares of BridgeBio Pharma by 46.8% in the 4th quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock worth $118,000 after buying an additional 935 shares during the period. EntryPoint Capital LLC purchased a new position in shares of BridgeBio Pharma in the 1st quarter worth $117,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of BridgeBio Pharma in the 3rd quarter worth $132,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Stock Performance

BBIO opened at $23.00 on Thursday. The stock has a market cap of $4.30 billion, a price-to-earnings ratio of -7.14 and a beta of 1.08. The stock’s 50 day moving average price is $27.43 and its 200-day moving average price is $31.81. BridgeBio Pharma has a one year low of $15.35 and a one year high of $44.32.

BridgeBio Pharma (NASDAQ:BBIOGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.35. The business had revenue of $211.12 million for the quarter, compared to the consensus estimate of $140.06 million. As a group, analysts predict that BridgeBio Pharma will post -3.2 earnings per share for the current fiscal year.

BridgeBio Pharma Company Profile

(Get Free Report

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

Recommended Stories

Analyst Recommendations for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.